Hansoh Pharma's B7-H3-Targeting ADC HS-20093 Granted New Clinical Trial Approval in China for Metastatic Colorectal Cancer

Aug 10, 2024 07:59 CST Updated 07:59

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

▎WuXi AppTec Content Team Report

On August 9, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) disclosed that Hansoh Pharma's Class 1 new drugHS-20093 for Injection Receives New Clinical Trial Implied Permission, Intended for Use in Combination with Bevacizumab (with or without Chemotherapy) or Cetuximab (with Chemotherapy)Patients with metastatic advanced colorectal cancerTreatment.Public information shows,HS-20093 is a novel antibody-drug conjugate (ADC) targeting B7-H3 developed by Hansoh Pharma. It consists of a humanized anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. In December 2023,GSK once reached a collaboration worth over $1.7 billion with Hansoh Pharma, obtaining the development, production, and commercialization rights for the drug in all regions outside of Greater China.

Screenshot source: CDEOfficial Website

HS-20093 is a novel ADC targeting B7-H3 developed by Hansoh Pharma.According toClinicalTrialsOfficial website, in July this year, researchers have registered an international multi-center Phase 3 clinical study (ARTEMIS-008), which aims to evaluate and compare HS-20093 with the standard of care (SOC) in terms of prolongingRecurrent Small Cell Lung CancerEfficacy in terms of overall survival (OS) for patients. This means that the product has entered the Phase 3 clinical research stage.

In addition, researchers are evaluating the efficacy of HS-20093 in treating various types of tumors in multiple phase 2 clinical studies, including recurrent or refractory bone and soft tissue sarcoma, metastatic castration-resistant prostate cancer, squamous cell carcinoma of the head and neck, esophageal cancer, and other advanced solid tumors.

This yearAmerican Society of Clinical Oncology (ASCO) Annual Meeting,Hansoh Pharma alsoOral ReportHS-20093 TreatmentPatients with Recurrent/Refractory OsteosarcomaThe phase 2 trial ARTEMIS-002 research data. The data showed that the disease control rate was 81.8% (9/11) in the group receiving 8 mg/kg HS-20093 treatment and 100% (10/10) in the group receiving 12.0 mg/kg HS-20093 treatment.

B7-H3: A New and Promising Target in Cancer TreatmentAs a transmembrane protein in the B7 family, B7-H3 is often overexpressed in various types of cancer. Studies show that inhibitors targeting B7-H3, including antibodies, ADCs, and radioimmunotherapy, represent a new class of anti-tumor drugs.According to public information, currently multiple products withB7-H3 isNew drugs targeting have entered phase 2 or 3 clinical research stages worldwide, including those from Hansoh Pharma.HS-20093 is one of the products with faster progress.

This timeHS-20093 Approved for Clinical Research Application in Colorectal Cancer Patients, Indicating Potential for Clinical Trials in New Tumor Types

References:

[1] Official website of the Center for Drug Evaluation, National Medical Products Administration of China. Retrieved Aug 9, 2024, from https://www.cde.org.cn/main/xxgk/listpage/da6efd086c099b7fc949121166f0130c

ThisThis article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media, but unauthorized reproduction by media or organizations in any form on other platforms is strictly prohibited.Reprint Authorization andFor other collaboration needs, please contact wuxi_media@wuxiapptec.com.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.